May 31, 2014 by Dave Williamson and Michael DouglassCDC Endorses HIV Prevention Drug: Investor TakeawaysGilead Sciences Inc. was already approved as an HIV preventative treatment, and now it has the CDC's endorsement.
May 31, 2014 by Dave Williamson and Michael DouglassAnti-Depressants: The Secret to Preventing Alzheimer's?Scientists are exploring the ways serotonin reuptake inhibitors might be able to slow Alzheimer's.
May 30, 2014 by Dave Williamson and Michael DouglassIs This Really the Best Pipeline In Biotech?ISIS Pharmaceuticals Inc. got a bump from Wall Street after its blood thinner received some positive clinical results.
May 30, 2014 by Dave Williamson and Michael DouglassChina Woes Continue to Haunt GlaxoSmithKline plcWill concerning allegations in China and in other countries impact GSK's bottom line?
May 30, 2014 by Dave Williamson and Michael DouglassArena vs Vivus: Which Obesity Stock is a Buy?Arena vs Vivus in a head to head competition of would you rather.
May 30, 2014 by Dave Williamson1 Big Pharma Stock in More Danger than Investors RealizeIs Eli Lilly's lost Alimta patent fight in the UK forshadowing bigger troubles for the big pharma?
May 30, 2014 by Dave Williamson and Michael DouglassPfizer Inc. Accelerates Its Next Great Blockbuster DrugPfizer's breast cancer drug palbociclib may go in front of the FDA early
May 30, 2014 by Dave Williamson and Michael DouglassSupreme Court + Risky Drug Launch = Billions at StakeTeva Pharmaceutical Industries Ltd. is trying, not all that successfully, to hold onto its money-making lead MS drug, Copaxone.
May 30, 2014 by Dave Williamson and Michael DouglassWhy Abbott Laboratories is Acquiring CFR PharmaceuticalsAbbott Laboratories makes a move in the Latin American market with its acquisition of generic-drugs company CFR Pharmaceuticals.
May 30, 2014 by Dave Williamson and Michael DouglassWould You Rather: Short Johnson & Johnson or Buy Dendreon?Johnson & Johnson and Dendreon face off in a game of
May 29, 2014 by Dave Williamson and Michael DouglassNo. 1 Draft Pick: Tremendous Upside or Total Bust?If you were drafting a drug in development for your biotech, what would be your No. 1 pick?
May 28, 2014 by Dave Williamson and Michael DouglassThe Beginning of the (Merciful) End for VIVUS, Inc Shareholders?Aspen Investment Fund may be taking Vivus private.
May 28, 2014 by Dave Williamson and Michael DouglassThe Biggest Loser of 2014's Mega Merger MessThe Pfizer and AstraZeneca mega deal is off, but who is the pressure on?
May 27, 2014 by Dave Williamson and Michael Douglass63% Implosion: The Epic Collapse of Provectus Biopharmaceuticals, IncProvectus' roller coaster ride has left investors nauseous.
May 25, 2014 by Dave Williamson and Michael DouglassAfter AstraZeneca: Pfizer's Next MovePicking up the pieces of Pfizer and AstraZeneca mega deal
May 20, 2014 by Dave Williamson and Michael Douglass25% Pop: Why Ophthotech Corp. Is Biotech's Newest StarEven after today's surge, investors need to pay close attention to Ophthotech
May 19, 2014 by Dave Williamson and Michael DouglassIs InterMune Inc. Your Next Biotech Buyout?InterMune's Esbriet won the day, but will it win the war to treat IPF?
May 17, 2014 by Dave Williamson1 Obesity Drug Stock the Market Got Completely WrongVivus first quarter results don't justify investor enthusiasm
May 16, 2014 by Dave Williamson and Michael DouglassBotox King Swings Back at "Unsustainable" AcquirerValeant needs to sharpen its spears to hunt Allergan.
May 13, 2014 by Dave WilliamsonWill Eli Lilly’s Groundbreaking Diabetes Victory Prove Hollow?Eli Lilly's new insulin is superior to Sanofi's Lantus, but safety may be its Achilles' heel.
